Business
Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor
Seasoned oncology drug development leader joins following early clinical proof-of-concept for WEE1 inhibitor, APR-1051DOYLESTOWN, Pa., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies that exploit cancer-specific vulnerabilities while minimizing damage to healthy cells, today announced the appointment of Eugene (Gene) Kennedy, MD, as Chief Medical Advisor. Dr. Kennedy j
About this update from Aprea Therapeutics, Inc.
[{"type":"image","alt":"Aprea Therapeutics","displaySize":"","headline":null,"caption":"Aprea Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":73,"url":"https://media.zenfs.com/en/globenewswire.com/99b3e900fb935fcf64456ae36360cec0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bNZPaglg_h8I4EDLnMTyIg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/99b3e900fb935fcf64456ae36360cec0","width":300,"height":73}},"lazy":false},{"type":"text","content":"Seasoned oncology drug development leader joins following early clinical proof-of-concept for WEE1 inhibitor, APR-1051","length":118,"tagName":"p"},{"type":"text","content":"DOYLESTOWN, Pa., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies that exploit cancer-specific vulnerabilities while minimizing damage to healthy cells, today announced the appointment of Eugene (Gene) Kennedy, MD, as Chief Medical Advisor.","length":368,"tagName":"p"},{"type":"text","content":"Dr. Kennedy joins Aprea at an important time, following the Company’s recent early clinical proof-of-concept demonstrated in its ongoing Phase 1 dose-escalation study evaluating the WEE1 inhibitor APR-1051 in patients with advanced solid tumors. He is a highly accomplished physician scientist and biopharmaceutical executive with more than 20 years of experience spanning oncology clinical development, regulatory strategy, and senior corporate leadership across both public and private biotechnology companies. Aprea believes his engagement will strengthen the Company’s clinical leadership as it advances dose escalation and refines patient selection for its WEE1-focused DNA damage response program.","length":703,"tagName":"p"},{"type":"text","content":"“We are excited to bring on a high caliber advisor such as Dr. Kennedy who has an extensive background in oncology drug development and experience across multiple stages of clinical development,” said Oren Gilad, PhD, Chief Executive Officer of Aprea Therapeutics. “His track record in leading and advancing complex oncology programs, working closely with regulators, and supporting data-driven decisions will be invaluable as we build on our recent early clinical proof-of-concept, opti...